Yair Lotan, MD, and Daniel Parker, MD join Ashish Kamat, MD, MBBS in a discussion on the efficacy and utilization of Blue Light Cystoscopy (BLC) Cysview® (hexaminolevulinate HCl). Dr. Lotanoffers his perspective on the use of blue light cystoscopy in bladder cancer detection in the hospital and Dr. Parker offers his perspective on the use in the office. Studies have shown that BLC improves the detection of bladder cancer at the time of transurethral resection of bladder tumor (TURBT) for nonmuscle-invasive bladder cancer, this has translated to decreased tumor recurrence and time to recurrence.
Dr. Lotan highlights indications for the use of BLC in the hospital including patients with a history of carcinoma in situ (CIS), concomitant CIS, patients with multifocal disease, patients who get referred who had a prior TURBT and is undergoing a repeat TUR, as well as patients with positive cytology under white light cystoscopy.
Dr. Parker turns our attention to the use of BLC in the ambulatory clinic. He highlights data in support of blue light cystoscopy in the office setting and offers his take on false positives, the increase in patient satisfaction scores for flexible blue light cystoscopy in the office setting with the avoidance of general anesthesia, the management of lesions in the office setting, as well as BLC being a potential avenue for improving costs and improving satisfaction associated with patients who can have these lesions dealt with satisfactorily outside of the operating room setting.
- Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, and holder of the Helen J. and Robert S. Strauss Professorship in Urology at UT Southwestern Medical Center
- Daniel Parker, MD, Assistant Professor in Urology, The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK
- Ashish Kamat, MD, MBBS, Professor, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, President, International Bladder Cancer Group (IBCG), Houston, Texas